Drug Pipeline

Anti-OX40 Antibody PF-04518600 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
4
Active Studies
0
Recruiting
1
Phase 3
4
Top Sponsors
Active Studies by Phase
Phase 3
1
Phase 2
2
Phase 1/2
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT05059522 Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab… Advanced Malignancies Active, Not Recruiting
Phase 2
NCT03971409 Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating… Stage III Breast Cancer Active, Not Recruiting
NCT03092856 Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With… Clear Cell Renal Cell Carcinoma Active, Not Recruiting
Phase 1/2
NCT03217747 Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating… Advanced Malignant Solid Neoplasm Active, Not Recruiting
Sponsors Running Anti-OX40 Antibody PF-04518600 Trials
University of Southern California (1) M.D. Anderson Cancer Center (1) Laura Huppert, MD, BA (1) Pfizer (1)
Disease Areas
Kidney Cancer (1) Prostate Cancer (1) Breast Cancer (1) Non-Small Cell Lung Cancer (NSCLC) (1) Ovarian Cancer (1)
Get alerts when Anti-OX40 Antibody PF-04518600 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free